Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: February 18, 2026
Principal Executive Office: Marseille, France
Context: This filing serves as a cover document for a press release dated February 18, 2026 (Exhibit 99.1). The text provided contains only the cover page and signature block; the content of the press release is not included in the source data.
Key Financial Metrics
The provided filing text does not contain financial statements or specific data points. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period. The specific nature of the update referenced in the attached press release is not disclosed in the cover document.
Guidance, Outlook, and Risks
Management commentary, future guidance, risk factors, contingencies, and unusual items are not present in the provided text. These details would be contained within the referenced Exhibit 99.1 (Press Release), which is not included in the input.
Investor Verification Checklist
- Verify the content of the attached Press Release (Exhibit 99.1) to understand the specific corporate event or announcement triggering this filing.
- Review the company's most recent Form 20-F or quarterly reports for the latest audited financial data, as this 6-K does not contain financial tables.
- Confirm if the announcement impacts the company's clinical trial pipeline or regulatory status, given the nature of the biopharmaceutical sector.